Sirtex Medical: Biotech Market Spotlight
Friday, 23 October, 2009
Oncology treatment company, Sirtex Medical (ASX:SRX) has continued to perform well, gaining 23c or 3.85% today as of 3pm to $6.20.
This follows a week of strong gains following an announcement on Monday of a 68% increase in operating profit from $3.25 million to $5.47 million for the last financial quarter.
The company also announced a dividend of 2c per share plus a special dividend of 5c per share to be paid in December.
Sirtex Medical, which manufactures SIR-Spheres for the treatment of liver cancer, saw revenues raise from $12.29 million to $16.47 million in the last quarter, a lift of 34%, in spite of a strengthening Australian dollar.
The company's stock has performed well over since the start of the year, with it seeing a 280% lift since January 2.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...